Simcere and Idorsia enter into a licensing agreement for daridorexant in China

NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options, announced today that they have entered into an exclusive licensing agreement for Idorsia's daridorexant in China.

Jinsheng Ren,Chairman and CEO of Simcere commented:

"This licensing agreement represents an important and exciting step in pursuing Simcere's mission of providing today's patients with medicines of the future. There are over 200 million people in China who suffer from chronic insomnia that may benefit from daridorexant. Patients are eager for a better treatment option that improves quality of sleep and next day functioning. Simcere has a proven track record of successfully developing and marketing innovative Central Nervous System therapies in China. In collaboration with Idorsia, we hope to bring another impactful medicine to millions of people."

Under the agreement, Simcere will be granted an exclusive right to develop and commercialize daridorexant in the Greater China region (Mainland China, Hong Kong, and Macau), one of the world's largest pharmaceutical markets. Simcere will be responsible for the funding and conducting of a local development program with Chinese patients. Simcere successfully commercializes Sanbexin for acute ischemic stroke and daridorexant will expand Simcere's pipeline of Central Nervous System (CNS) products in China.